Skip to main content
. 2021 Apr 18;9(4):437. doi: 10.3390/biomedicines9040437

Figure 3.

Figure 3

BET inhibition decreased SARS-CoV-2 spike RBD binding to Calu-3 and Vero E6. (A) A histogram overlay representing the binding of SARS-CoV-2 spike RBD Fc fusion protein to Calu-3 following 48 h of apabetalone or JQ1 treatment at the indicated concentrations. (B,C) Quantification of BETi-driven changes to SARS-CoV-2 spike RBD binding to Calu-3 (B; n = 3) or Vero E6 (C; n = 3) cells following 48 h of treatment. Binding results are shown as mean fluorescent intensity (MFI) ratio to Fc control. Error bars represent SD. * p < 0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA followed by Dunnett’s multiple comparison test.